Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 11/20 | 0.41 |
| ▸ | CCNK | O75909 | 11/20 | 0.41 |
| ▸ | CDK9 | P50750 | 11/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 11/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.41 |
| ▸ | CDK2 | P24941 | 9/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 10/20 | 0.40 |
| ▸ | CCNH | P51946 | 9/20 | 0.40 |
| ▸ | MNAT1 | P51948 | 8/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25294691 | 1.00 | CCNT1 (0.41) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL30833890 | 0.82 | IDH2 (0.41) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25302099 | 0.73 | KAT2B (0.39) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25302097 | 0.73 | KAT2B (0.39) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL31197278 | 0.72 | CDK7 (0.43) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL24695415 | 0.71 | CCNT1 (0.47) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL25301972 | 0.70 | CCNT1 (0.43) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29326100 | 0.70 | HSD11B1 (0.37) | CRBN | |
| SCHEMBL25301974 | 0.70 | CCNT1 (0.43) | CCNT1CCNKCDK9CDK12CCNE1 | |
| SCHEMBL29326088 | 0.70 | HPGDS (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613749-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2025-09-10 | — | — | EP | disclosed |
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-15 | — | — | US | disclosed |
| CN-119798221-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| EP-4461729-A1 | ANTIGEN BINDING PROTEIN TARGETING MSLN AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2024-11-13 | — | — | EP | disclosed |
| CN-117986258-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| CN-116410140-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2023-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | NLRP3, NLRP1, PYCARD | CCNT1 4848/4885CCNK 4590/4885CDK9 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.